GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Price-to-Owner-Earnings

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 1993. Start your Free Trial

As of today (2024-04-19), Fresh Tracks Therapeutics's share price is $0.9003. Fresh Tracks Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Fresh Tracks Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Fresh Tracks Therapeutics was 3468.68. The lowest was 0.00. And the median was 3049.78.


FRTX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-19), Fresh Tracks Therapeutics's share price is $0.9003. Fresh Tracks Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.41. Therefore, Fresh Tracks Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-19), Fresh Tracks Therapeutics's share price is $0.9003. Fresh Tracks Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.41. Therefore, Fresh Tracks Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 13 years, Fresh Tracks Therapeutics's highest PE Ratio without NRI was 203.00. The lowest was 0.00. And the median was 168.00.


Fresh Tracks Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Fresh Tracks Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Price-to-Owner-Earnings falls into.



Fresh Tracks Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Fresh Tracks Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.9003/-1.07
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh Tracks Therapeutics  (OTCPK:FRTX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Fresh Tracks Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Headlines